An Overview of the ARANOTE Trial

Now Viewing

EP: 1.An Overview of the ARANOTE Trial

EP: 2.Comparing Trials Studying Treatment Intensification In mHSPC

EP: 3.Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses

EP: 4.Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT

EP: 5.Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

EP: 6.Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC

EP: 7.Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point

EP: 8.Using Ultrasensitive PSA Assays in Routine Practice

EP: 9.The Use of Ultra-Low PSA in Specific Patient Profiles

EP: 10.Selecting Between Receptor Pathway Inhibitors for mHSPC

Advanced Prostate Cancer Treatment Strategies

Panel Introduction

Featured Expert:

• Neal D. Shore, MD, FACS: Medical oncologist and urologist at Carolina Urologic Research Center, Myrtle Beach, South Carolina. Dr Shore is a recognized researcher in urologic oncology with expertise in clinical trials for advanced prostate cancer treatments.

Expert Specialty Areas

• Urologic oncology
• Clinical research in metastatic hormone-sensitive prostate cancer (mHSPC)
• Novel androgen receptor pathway inhibitors
• Prostate-specific antigen response as predictive biomarker

ARANOTE Trial Overview

Key Themes:

• Phase 3 clinical trial evaluating darolutamide plus ADT in patients with mHSPC
• Trial design and methodology
• Significant efficacy outcomes

Expert Insights:

• Dr Shore provided an overview of the ARANOTE trial design, which evaluated darolutamide in combination with androgen deprivation therapy (ADT) for patients with mHSPC.
• The discussion highlighted the topline results demonstrating clinical benefit with this treatment approach.